REVIEW ARTICLE
Cytotoxic Activity of CD48 Monoclonal Antibodies Against Human Lymphoma Cells
Jiewei Wei1, David Y. Chin1, 2, Stephen M. Mahler1, 2, *
Article Information
Identifiers and Pagination:
Year: 2008Volume: 2
First Page: 219
Last Page: 223
Publisher ID: TOBIOTJ-2-219
DOI: 10.2174/1874070700802010219
Article History:
Received Date: 29/05/2008Revision Received Date: 04/07/2008
Acceptance Date: 08/07/2008
Electronic publication date: 4/8/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: (https://creativecommons.org/licenses/by/4.0/legalcode). This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
CD48 is a cell surface, glycosylphosphatidylinositol-linked glycoprotein, and a potential target for treatment of leukemia and lymphoma. Two anti-CD48 mAbs, murine HuLy-m3 and human IgG1-N2A, were compared in cellular assays using a human lymphoma cell line (Raji) for their ability to inhibit cell growth and induce apoptosis. In vitro studies revealed both HuLy-m3 and IgG1-N2A mAbs were able to induce potent growth inhibition, reflected by a reduction in viable cells of approximately 70% compared to controls after 90 h. Furthermore, Raji cells treated with IgG1-N2A showed evidence of apoptosis, including increased ethidium bromide uptake, cell shrinkage and chromosomal DNA degradation.